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Background: The relationship between brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels 
and risk of cardiovascular events in patients with heart failure (HF) has been demonstrated in previous studies. However, it is unclear whether 
changes of BNP and NT-proBNP predict clinical events in HF patients. The aim of the study was to explore the association between changes in neuro-
hormonal activation and mortality/morbidity in HF patients.
Methods: The MEDLINE, Cochrane, ISI Web of Science and SCOPUS database were searched for articles about HF treatment until November 
2011. Randomized trials assessing BNP and/or NT-proBNP at baseline and at end of follow-up and reporting clinical end-points (all-cause death 
and hospitalization for HF) were included in meta-analysis. Meta-regression analysis was performed to test the relationship between BNP and NT-
proBNP changes and two clinical end-points: all-cause death and the composite of all-cause death and HF hospitalization. The influence of baseline 
patients’ characteristics, BNP and NT-proBNP at baseline and at end of study, follow-up and study publication year were also explored. Macaskill’s 
modified test was used to assess publication bias.
Results: 27 trials enrolling 15,820 participants were included. In meta-regression analysis, no relationship between BNP changes from baseline to 
end of follow-up and outcomes was detected (all-cause death: t=0.66, p=0.52; composite outcome: t=0.19, p=0.85). Similarly, NT-proBNP changes 
did not correlate to all-cause death (t=2.38, p=0.08) whereas they correlated to changes of the composite outcome (t=2.95, p=0.03). By sensitivity 
analysis no influence of potentially confounder variables was observed and no publication bias was detected.
Conclusions: In HF patients, changes of neuro-hormonal peptides levels do not predict the effects of therapies on all-cause death, but, for NT-
proBNP, correlate to the combined occurrence of all-cause death and HF hospitalization.
